Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma

  • Nakhle S. Saba
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
  • Delong Liu
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
  • Sarah E. M. Herman
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
  • Chingiz Underbayev
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
  • Xin Tian
    Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
  • David Behrend
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
  • Marc A. Weniger
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
  • Martin Skarzynski
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
  • Jennifer Gyamfi
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
  • Lorena Fontan
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY;
  • Ari Melnick
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY;
  • Cliona Grant
    Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;
  • Mark Roschewski
    Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;
  • Alba Navarro
    Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain; and
  • Sílvia Beà
    Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain; and
  • Stefania Pittaluga
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
  • Kieron Dunleavy
    Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;
  • Wyndham H. Wilson
    Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;
  • Adrian Wiestner
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;

書誌事項

公開日
2016-07-07
DOI
  • 10.1182/blood-2015-11-681460
公開者
American Society of Hematology

この論文をさがす

説明

<jats:title>Key Points</jats:title> <jats:p>Activation of BCR and canonical NF-κB signaling in the lymph node correlates with survival in MCL. Mutations and polymorphisms in BCR and NF-κB pathways may confer cell autonomous signaling and affect response to ibrutinib.</jats:p>

収録刊行物

  • Blood

    Blood 128 (1), 82-92, 2016-07-07

    American Society of Hematology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ